View More Recent Stories
-
TD Cowen Upgrades CVS Health (CVS) to Buy
-
Attorney General Ken Paxton Sues Big Pharma Drug Manufacturers and Pharmacy Benefit Managers for Conspiracy That Increased Insulin Prices by 1,000%
-
Morgan Stanley Reiterates Overweight Rating on CVS Health (CVS)
-
Mizuho Reiterates Outperform Rating on CVS Health (CVS)
-
Leerink Partners Reiterates Market Perform Rating on CVS Health (CVS)
-
Evercore ISI Reiterates Outperform Rating on CVS Health (CVS)
-
Glenview Capital Prepares for Activist Push at CVS Health (CVS) - WSJ (earlier)
-
FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices
-
CVS Health (CVS) Declares $0.665 Quarterly Dividend; 4.5% Yield
-
10 most actionable policies if Harris wins & stock implications: Jefferies
-
CVS Health (CVS) Appoints Heidi Capozzi as Chief People Officer
-
TD Cowen Reiterates Hold Rating on CVS Health (CVS)
-
CVS Health (CVS) PT Lowered to $63 at Deutsche Bank
-
Midday movers: Super Micro Computer, Airbnb and Lyft fall; Shopify rises
-
CVS Health (CVS) cuts full-year EPS guidance on continued pressure in the health care benefits unit
-
CVS Health (CVS) Tops Q2 EPS by 10c; cuts profit guidance
-
CVS Health (CVS) call put ratio 1.3 calls to 1 put into quarter results
-
CVS Health (CVS) August 9 weekly 58 straddle priced into quarter results
-
Sunrun (RUN), Other Solar Stocks Decline Following Assassination Attempt on Trump
-
FTC to Sue Drug Managers over Insulin Prices - WSJ
-
TD Cowen Reiterates Hold Rating on CVS Health (CVS)
-
CVS Health (CVS) Trades Lower in Sympathy with Walgreens (WBA)
-
RBC Capital on Walgreens (WBA): 'ongoing consumer weakness and pressure on pharmacy margin'
-
Medicare Advantage Plans Quality Ratings To Be Recalculated - WSJ

